Aurobindo Pharma Q1 Profit Rises 25% on Strong Revenue Growth and Margin Expansion

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628

reported a strong performance for the first quarter of FY27, with consolidated net profit rising 25% year-on-year to ₹1,030 crore. Revenue from operations increased 16% to ₹9,150 crore, driven by broad-based growth across its formulations and active pharmaceutical ingredients (API) businesses, supported by healthy demand in key international markets. The company's operating performance also improved significantly. EBITDA grew 19% year-on-year to ₹2,259 crore, while the EBITDA margin expanded to 24.7% from 24.1% a year earlier, reflecting improved product mix and operational efficiencies. Growth was led by higher sales in the Europe formulations, growth markets, and API segments, while the company continued to benefit from new product launches and a diversified global portfolio. Research and development expenditure remained focused on strengthening its future product pipeline and expanding its presence across regulated markets. Industry & Economic Impact: The results reflect the continued strength of India's pharmaceutical industry, supported by robust global demand for generic medicines, specialty products, and APIs. Improved profitability and expanding margins highlight the sector's focus on operational efficiency, product diversification, and value-added manufacturing. From an economic perspective, sustained growth in pharmaceutical manufacturing supports exports, high-value manufacturing, research and development, and skilled employment. Continued expansion by companies like Aurobindo Pharma strengthens India's position as a global pharmaceutical hub while contributing to long-term industrial and economic growth. Source: Economic Times No Recommendations